FDA Grants Fast Track Designation to Atox Bio's AB103 for the Treatment of Necrotizing Soft Tissue Infections (NSTI)  
9/10/2012 9:23:06 AM

NESS ZIONA, Israel--(BUSINESS WIRE)--Atox Bio, a clinical stage biotechnology company engaged in the development of novel immunemodulators for severe infections in critically ill patients, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to AB103, its lead product, currently in development for the treatment of Necrotizing Soft Tissue Infections (NSTI).